Abstract 275P
Background
In 2022, the U.S. Food and Drug Administration (FDA) approved Lutetium-177 Prostate-specific membrane antigen (Lu-177 PSMA). This approval was based on the VISION trial, in which Lu-177 PSMA demonstrated improved progression-free survival (PFS) and overall survival (OS) compared to standard therapy alone. PSMA is more strongly expressed in prostate cancer than in benign prostatic hyperplasia and correlates with Gleason Score and cancer grade. PSMA is involved in tumor growth by activating IP3K-AKT-mTOR signaling through folate metabolism. PSMA expression is suppressed by androgen receptor (AR) bound complexes with testosterone and promoted by unbound AR. In other words, inhibition of AR signaling enhances PSMA expression. These findings suggest that PSMA is involved in the mechanism of resistance to treatment in castration resistant prostate cancer (CRPC). Our previous study also showed that CRPC patients with PSMA expression in the blood circulating tumor cells (CTCs) have a shorter PFS. In this study, we aimed to determine the association between PSMA expression in CTCs and OS after the initiation of taxane-based chemotherapies in metastatic CRPC.
Methods
Forty-eight patients with metastatic CRPC treated with docetaxel followed by cabazitaxel were included in the study. PSMA expression in CTCs was analyzed over time, and the association between PSMA expression and OS was analyzed.
Results
Twenty-seven patients were positive for PSMA expression, and 21 patients were negative for PSMA expression in CTC. The analysis comparing patient backgrounds showed no significant differences with respect to Gleason Score, number of docetaxel treatments, prior ARATs administration, or metastatic site. On the other hand, patients with positive PSMA showed a longer time to acquire castration resistance. The log-rank test result showed shorter OS after initiation of docetaxel treatment in patients with positive PSMA than in those with negative PSMA (median survival at observation, PSMA-positive group: 618 days; PSMA-negative group: 1187 days; P=0.05).
Conclusions
The expression of PSMA in CTCs was associated with OS after initiation of taxane-based chemotherapy in metastatic CRPC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
571P - Dacomitinib in treatment-naïve EGFR-mutant NSCLC patients with multiple brain metastases: Initial efficacy and safety data from a phase II study
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
572P - Multivariable five-year survival prediction model for prognosing patients with EGFR-mutated NSCLC treated with EGFR-TKIs
Presenter: Qi-An Wang
Session: Poster Display
Resources:
Abstract
573P - LUMINATE-103: Real-world treatment patterns and outcomes of patients (pts) with epidermal growth factor receptor mutant (EGFR MU), non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC): Pooled analysis of large US electronic health record (EHR) datasets
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract
574P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutations
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
575P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC and brain metastasis: A multicenter cohort study
Presenter: Puyuan Xing
Session: Poster Display
Resources:
Abstract
576P - Clonality of both EGFR and co-occurring TP53 mutations affect the treatment efficacy of the third-generation EGFR-TKIs in advanced-stage EGFR-mutant non-small cell lung cancer
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
577P - A study of the efficacy and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in NSCLC
Presenter: Daeho Choi
Session: Poster Display
Resources:
Abstract
578P - Tyrosine kinase inhibitor treatment of elderly patients with epidermal growth factor receptor mutated advanced non-small cell lung cancer: A multi-institute retrospective study
Presenter: Ling-Jen Hung
Session: Poster Display
Resources:
Abstract
579P - Real-world study of dacomitinib as first-line treatment for patients with EGFR-mutant non-small cell lung cancer
Presenter: Ji Eun Shin
Session: Poster Display
Resources:
Abstract
580P - Efficacy and safety of dacomitinib as first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor <italic>(EGFR)</italic> 21L858R mutation: A multicenter, ambispective, consecutive case-series study
Presenter: Shouzheng Wang
Session: Poster Display
Resources:
Abstract